Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability

Wa Zhang; David Klinkebiel; Carter J Barger; Sanjit Pandey; Chittibabu Guda; Austin Miller; Stacey N. Akers; Kunle Odunsi; Adam R. Karpf

doi:10.1101/2020.01.22.20018374

Abstract

A hallmark of human cancer is global DNA hypomethylation (GDHO), but the mechanisms accounting for this defect and its pathological consequences have not been defined in human epithelial ovarian cancer (EOC). In EOC, GDHO was associated with advanced disease and reduced overall and disease-free survival. GDHO(+) EOC was enriched for a proliferative gene expression signature, including CCNE1 and FOXM1 overexpression. DNA hypomethylation preferentially occurred within genomic blocks (hypomethylated blocks) overlapping late-replicating, lamina-associated domains, PRC2 binding, and H3K27me3. Increased proliferation coupled with hypomethylated block formation at late replicating regions suggested passive hypomethylation, which was further supported by the observation that cytosine DNA methyltransferases (DNMTs) and UHRF1 showed significantly reduced expression in GDHO(+) EOC, after normalization to proliferation markers. Importantly, GDHO(+) EOC showed elevated chromosomal instability (CIN), and copy number alterations (CNA) were enriched at hypomethylated blocks. Together, these findings implicate a passive demethylation mechanism for GDHO that promotes genomic instability and poor prognosis in EOC.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

All funding is reported in the contents of the manuscript.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data is provided in the contents of the manuscript.

Non-standard abbreviations

CG gene: cancer germline or cancer testis gene
CIN: chromosomal instability
CNA: copy number alteration
DAC: decitabine, 5-aza-2’-deoxycytidine
DEG: differentially expressed gene
DE-CG gene: differentially expressed CG gene
DMC: differentially methylated CpG site
DMR: differentially methylated region
DNMT: cytosine DNA methyltransferase
EOC: epithelial ovarian cancer
FDR: false discovery rate
FTE: fallopian tube epithelia
GDHO: global DNA hypomethylation
GSEA: gene set enrichment analysis
HGSOC: high grade serous ovarian cancer
IPA: Ingenuity Pathway Analysis
LAD: lamina-associated domain
NE: normal epithelia (OSE + FTE)
NO: bulk normal ovary
OSE: ovarian surface epithelia
PCA: principal component analysis
RE: repetitive DNA elements
RMA: robust multichip average
TET: Ten-eleven translocation methylcytosine dioxygenase
TF: transcription factor

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.